Extended Data Fig. 3: Kaplan-Meier analysis of PFS by investigator in (a) HR+ and (b) HR− cohorts. | Nature Medicine

Extended Data Fig. 3: Kaplan-Meier analysis of PFS by investigator in (a) HR+ and (b) HR− cohorts.

From: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

Extended Data Fig. 3

CI, confidence interval; HR, hormone receptor; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician’s choice of chemotherapy. For the OS and PFS by investigator endpoints for the HR+ and all patient cohorts, the HR status is based on data collected using the interactive web-response and voice-response system at the time of randomization, which includes patients who were misstratified.

Back to article page